4.8 Article

Changes in serum hepatitis B surface and e antigen, interferon-inducible protein 10, and aminotransferase levels during combination therapy of immune-tolerant chronic hepatitis B

Journal

HEPATOLOGY
Volume 76, Issue 3, Pages 775-787

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1002/hep.32400

Keywords

-

Funding

  1. NIDDK [U01-DK082843, U01-DK082863, U01-DK082864, U01-DK082866, U01-DK082867, U01-DK082871, U01-DK082872, U01-DK082874, U01-DK082919, U01DK082923, U01-DK082927, U01-DK082943, U01-DK082944, U01-DK082916, A-DK-3002-001]
  2. NIH/NIDDK Center of Molecular Studies in Digestive and Liver Diseases [P30DK50306]
  3. NIH Public Health Service Research [M01-RR00040]
  4. NCATS (National Center for Advancing Translational Sciences, NIH) [UL1TR000058]
  5. Norah A. Terrault, MD, MPH (CTSA) [UL1TR000004]
  6. Michael W. Fried, MD (CTSA) [UL1TR001111]
  7. Kathleen B. Schwarz, MD (CTSA) [UL1 TR000423]
  8. Anna Suk--Fong Lok (CTSA) [UL1RR024986, U54TR001959]
  9. Roche Molecular Systems, Inc.
  10. NIDDK

Ask authors/readers for more resources

In immune-tolerant children and adults with chronic hepatitis B infection, combined treatment with peginterferon alfa-2a and entecavir resulted in a decline in serum HBeAg and HBsAg concentrations but rarely led to loss of HBeAg or sustained off-treatment response. The induction of IP-10 during peginterferon treatment was associated with ALT elevations and decline in viral antigens.
Background and Aims Treatment of immune-tolerant (IT) children and adults with combined peginterferon alfa-2a and entecavir results in a decline in serum HBeAg and HBsAg concentrations but rarely results in loss of HBeAg or sustained off-treatment response. Factors associated with declines in these viral antigens during treatment remain unexplored. Approach and Results We investigated the pattern of virologic and biochemical response in 86 participants (59 children, 27 adults) by serial quantitative measurement of HBsAg (qHBsAg), quantitative HBeAg (qHBeAg), HBV RNA, interferon-inducible protein (IP-10), IL-18, and alanine aminotransferase (ALT). Each individual had previously been treated with 8 weeks of entecavir followed by 40 weeks of combined peginteferon and entecavir. We defined the interrelationships between these parameters and virologic response measured as nadir declines from baseline for HBeAg and HBsAg. The patterns of HBsAg and HBeAg decline were similar in pediatric and adult participants. Higher levels of IP-10 were observed during treatment in participants with greater ALT elevations and greater reductions of qHBsAg and qHBeAg. Individuals with peak ALT values exceeding three times the upper limit of normal were significantly more likely to have >1 log(10) decline in both viral antigens. HBV DNA became undetectable in 21 of 86 (24%) and HBV RNA in 4 of 77 (5%) during therapy, but both markers remained negative only in those who became HBsAg negative, all of whom also had ALT elevations. Conclusions Induction of IP-10 during peginterferon treatment in adults and children in the IT phase of chronic HBV infection is associated with ALT elevations and decline in viral antigens, suggesting a degree of interferon-inducible viral control.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available